Human Growth Hormone Market Report by Application, Distribution Channel, Route of Administration, and Region 2024-2032
인간성장호르몬 세계 시장 규모는 2023년 57억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장 규모가 2024-2032년 사이 7.2%의 연평균 성장률(CAGR)로 109억 달러에 달할 것으로 예상하고 있습니다.
HGH는 뇌하수체에서 분비되는 펩타이드 호르몬으로 어린이와 성인의 성장을 촉진합니다. 이 호르몬은 주로 세포의 성장, 재생, 복구, 재생산 및 신진대사를 조절하여 신체의 전반적인 발달에 기여합니다. 또한 체액, 지방 대사, 뼈와 근육의 성장을 조절하며, HGH가 부족하면 질병과 지방 축적의 위험이 증가하지만, 고농도에서는 소아에서는 거대증, 성인에서는 말단 거대증, 근력 약화, 단장 증후군을 유발할 수 있습니다.
터너 증후군 및 기타 성장 관련 질환의 유병률 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 터너 증후군은 주로 여성에게 발생하는 염색체 이상으로 X 염색체의 전체 또는 부분적인 손실이 특징입니다. 성장호르몬은 종종 이 질환의 일부 증상을 회복하기 위해 투여되며, 이로 인해 전 세계적으로 HGH 의약품에 대한 수요가 증가하고 있습니다. 또한, 대중의 건강 인식이 높아지고 내분비 질환 예방 조치에 대한 인식이 높아짐에 따라 시장 성장에 기여하고 있습니다. 프라더 윌리 증후군(PWS)과 특발성 저신장증(ISS)과 같은 다양한 질병은 체내 성장호르몬 결핍으로 인해 발생하며, 의료용으로 합성된 HGH를 사용하여 치료할 수 있습니다. 보디빌더들의 성능 향상제로서의 HGH 사용 증가와 유전자재조합 인간성장호르몬(rHGH)의 시장 개척 등 다른 요인들도 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 다루는 주요 질문들
- 인간성장호르몬 세계 시장 규모는?
- 2024-2032년 세계 인간성장호르몬 시장의 예상 성장률은?
- 인간성장호르몬 세계 시장을 이끄는 주요 요인은 무엇인가?
- COVID-19가 세계 인간성장호르몬 시장에 미치는 영향은?
- 인간성장호르몬 세계 시장 용도별 분류는?
- 인간성장호르몬 세계 시장 내 판매 채널별 분류는?
- 투여 경로별 인간성장호르몬 세계 시장 현황은?
- 인간성장호르몬 세계 시장 주요 지역은?
- 인간성장호르몬 세계 시장 주요 진출 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 인간성장호르몬 세계 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 용도별
- 성장호르몬(GH) 결핍증
- 터너증후군
- 특발성 저신장 증(ISS)
- 프라더 윌리-증후군(PWS)
- 임신 입덧
- 기타
제7장 시장 내역 : 유통 채널별
제8장 시장 내역 : 투여 경로별
제9장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제13장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Eli Lilly and Company
- EMD Serono Inc.
- F. Hoffmann-La Roche AG
- Ferring B.V.
- Genentech Inc.
- Ipsen
- Merck KGaA
- Novartis AG
- Novo Nordisk
- Pfizer Inc.
- Sandoz
ksm
The global human growth hormone market size reached US$ 5.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 10.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.2% during 2024-2032.
HGH is a peptide hormone that is produced by the pituitary gland to stimulate growth in children and adults. The hormone primarily regulates growth, regeneration, repair, reproduction and metabolism of the cells, thus contributing to the overall development of the body. It also regulates body fluids, fat metabolism and bone and muscle growth. The deficiency of HGH can increase the risk of diseases and fat accumulation, whereas higher levels can cause gigantism in children and acromegaly, muscle-wasting disease and short bowel syndrome in adults.
The increasing prevalence of Turner syndrome and other growth-related disorders is one of the key factors driving the growth of the market. Turner syndrome is a chromosomal disorder that primarily affects females and is characterized by complete or partial loss of X chromosomes. Growth hormones are often administered to reverse some of the symptoms of this disease, thereby increasing the demand for HGH drugs across the globe. Furthermore, increasing health consciousness among the masses and growing awareness regarding the preventive measures against endocrine disorders, are providing a boost to the market growth. Various disorders, such as Prader-Willi syndrome (PWS) and idiopathic short stature (ISS), are caused by the deficiency of growth hormones in the body that can be treated using medically synthesized HGH. Other factors, including a rising utilization of HGH as performance enhancers by bodybuilders, along with the development of recombinant human growth hormone (rHGH), are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global human growth hormone market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application, distribution channel and route of administration.
Breakup by Application:
Growth Hormone (GH) Deficiency
Adult GH Deficiency
Pediatric GH Deficiency
Turner Syndrome
Idiopathic Short Stature (ISS)
Prader-Willi Syndrome (PWS)
Small for Gestational Age
Others
Breakup by Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Breakup by Route of Administration:
Intravenous
Intramuscular
Subcutaneous
Oral
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Eli Lilly and Company, EMD Serono Inc., F. Hoffmann-La Roche AG, Ferring B.V., Genentech Inc., Ipsen, Merck KGaA, Novartis AG, Novo Nordisk, Pfizer Inc., Sandoz, etc.
Key Questions Answered in This Report
- 1. How big is the global human growth hormone market?
- 2. What is the expected growth rate of the global human growth hormone market during 2024-2032?
- 3. What are the key factors driving the global human growth hormone market?
- 4. What has been the impact of COVID-19 on the global human growth hormone market?
- 5. What is the breakup of the global human growth hormone market based on the application?
- 6. What is the breakup of the global human growth hormone market based on the distribution channel?
- 7. What is the breakup of the global human growth hormone market based on the route of administration?
- 8. What are the key regions in the global human growth hormone market?
- 9. Who are the key players/companies in the global human growth hormone market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Human Growth Hormone Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Application
- 6.1 Growth Hormone (GH) Deficiency
- 6.1.1 Market Trends
- 6.1.2 Major Types
- 6.1.2.1 Adult GH Deficiency
- 6.1.2.2 Pediatric GH Deficiency
- 6.1.3 Market Forecast
- 6.2 Turner Syndrome
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Idiopathic Short Stature (ISS)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Prader-Willi Syndrome (PWS)
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Small for Gestational Age
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Distribution Channel
- 7.1 Hospital Pharmacy
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Retail Pharmacy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Online Pharmacy
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Route of Administration
- 8.1 Intravenous
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Intramuscular
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Subcutaneous
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Oral
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Eli Lilly and Company
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 EMD Serono Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.3 F. Hoffmann-La Roche AG
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 SWOT Analysis
- 13.3.4 Ferring B.V.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.5 Genentech Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 SWOT Analysis
- 13.3.6 Ipsen
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.7 Merck KGaA
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.8 Novartis AG
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.9 Novo Nordisk
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.10 Pfizer Inc.
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.11 Sandoz
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
